ILK-IN-2

ILK-IN-2 is an inhibitor of integrin-linked kinase (ILK, IC50 = 0.6 µM). It inhibits the phosphorylation of Akt, glycogen synthase kinase 3beta (GSK3beta), and myosin light-chain (MLC) in PC3 prostate and MDA-MB-231 breast cancer cells when used at concentrations ranging from 1 to 4 µM. ILK-IN-2 inhibits the proliferation of LNCaP, PC3, MDA-MB-231, MDA-MB-468, SK-BR-3, and MCF-7 cancer cells (IC50s = 1.6, 2, 1, 1.5, 1.8, and 2.5 µM, respectively), as well as induces autophagy and apoptosis in PC3 cells when used at a concentration of 2 µM. It also reduces protein levels of Y-box binding protein (YB-1), HER2, and EGFR in PC3 cells. ILK-IN-2 (25 and 50 mg/kg) reduces tumor growth in a PC3 mouse xenograft model.Formal Name: N-methyl-1-[4-(1-piperazinyl)phenyl]-5-[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]-1H-pyrazole-3-propanamide. CAS Number: 1333146-24-9. Synonyms: CPD 22, Integrin-linked Kinase Inhibitor 1, OSU-T 315. Molecular Formula: C30H30F3N5O. Formula Weight: 533.6. Purity: >98%. Formulation: (Request formulation change), A solid. Solubility: DMSO: 10mM. lambdamax: 269 nm. SMILES: FC(F)(F)C1=CC=C(C2=CC=C(C3=CC(CCC(NC)=O)=NN3C4=CC=C(N5CCNCC5)C=C4)C=C2)C=C1. InChi Code: InChI=1S/C30H30F3N5O/c1-34-29(39)15-10-25-20-28(38(36-25)27-13-11-26(12-14-27)37-18-16-35-17-19-37)23-4-2-21(3-5-23)22-6-8-24(9-7-22)30(31,32)33/h2-9,11-14,20,35H,10,15-19H2,1H3,(H,34,39). InChi Key: GHBUPSVATJKTRR-UHFFFAOYSA-N.